My site

INGELHEIM, Germany - Tuesday, September 2nd 2014 [ME NewsWire]

    RE-LY® sub-analysis shows that Pradaxa® treatment favourably affects kidney function1 deterioration over time compared to warfarin
    Data provide additional support for long-term use of Pradaxa® in stroke prevention in non-valvular atrial fibrillation (NVAF)1

(BUSINESS WIRE)-- Non-US/Non-UK/Non-Canadian Media

New data presented today indicate that kidney function decline is less pronounced in patients with an irregular heartbeat (non-valvular atrial fibrillation, NVAF) who are treated with Pradaxa®(dabigatran etexilate) compared to warfarin.1 A natural decline in kidney function is expected as part of the ageing process or as a result of other underlying diseases.2 New data support that long-term Pradaxa® treatment compares favourably to warfarin in terms of kidney function decline over time.1 The new RE-LY® study sub-analysis findi ... Read more »

SAN FRANCISCO. - Tuesday, September 2nd 2014 [ME NewsWire]

(BUSINESS WIRE) WTAS, one of the nation’s largest independent tax firms, has acquired the rights to the iconic brand name Andersen and will rename itself Andersen Tax.

Founded in 2002 by CEO Mark Vorsatz and 22 former Arthur Andersen partners, WTAS’ strong international growth required a common identity for its global presence. In an effort to identify a brand name that it could use and protect globally, WTAS felt the ‘Andersen’ name best reflected its own culture of clients first, stewardship, transparency and best in-class solutions.

“We all came from a common culture and shared certain core values,” said CEO Mark Vorsatz. “In creating a global platform, we recognized that the development of an integrated professional service model based on common values with a common identity was essential.”

Andersen Tax, like WTAS, will be an independent glob ... Read more »

NEW YORK - Tuesday, September 2nd 2014 [ME NewsWire]

(BUSINESS WIRE)-- Moelis & Company (NYSE:MC), a leading global independent investment bank, today announced the appointment of Eric Cantor, former United States Representative for Virginia’s 7thCongressional District and former House Majority Leader, as Vice Chairman and Managing Director. Mr. Cantor will also be elected to the Moelis & Company Board of Directors.

In his new role, Mr. Cantor will provide strategic counsel to the Firm’s corporate and institutional clients on key issues. He will play a leading role in client development and advise clients on strategic matters.

Ken Moelis, Chairman and CEO of Moelis & Company, said, “At Moelis & Company, we offer our clients judgment and experience in order to help them with their most important strategic and financial decisions. Eric’s judgment and tremendous experience will expand the capabilities our team brings to cl ... Read more »

INGELHEIM, Germany. - Monday, September 1st 2014 [ME NewsWire]

    Recent analysis of real world data document again the positive safety and efficacy profile of Pradaxa® as proven in clinical trials1-3
    Final Phase of GLORIA™-AF Registry Program now initiated in North America and Europe
    Extensive clinical research in established and new indications underway to improve patient care with Pradaxa®

(BUSINESS WIRE) For Non-US/Non-UK/Non-Canadian Media

Five years on from the first breakthrough presentation of the pivotal RE-LY® clinical trial of Pradaxa® (dabigatran etexilate) for the prevention of stroke in non-valvular atrial fibrillation (NVAF),4 extensive clinical trial and real-world data support Pradaxa® in various indications.1-12 Boehringer Ingelheim continues to grow the evidence base for Pradaxa® to improve care for patients at risk of blood clots and today annou ... Read more »